Jazz Pharmaceuticals plc looks very undervalued at 2.4x sales as oncology catalysts (Ziihera, Zepzelca, Epidiolex) drive ...

Sun Pharma's Managing Director, Kirti Ganorkar, predicts that new age medicines for obesity and diabetes will drive the ...

Indian pharmaceutical market (IPM) has registered a growth of 8.1 percent to touch ₹2,40,672 crore in 2025 and is likely to ...

Royalty Pharma reports Q1 2025 financials with 17% portfolio receipts growth, raising 2025 guidance to $2,975-$3,125 million. Royalty Pharma plc announced its financial results for the first quarter ...

Vertex Pharmaceuticals is anchored by cystic fibrosis as launches lag, JOURNAVX and CASGEVY add little revenue, and growth is ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest ...

NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) will host an Investor Day in New York City today. Senior executives will provide an update on the company’s plans to ...

In a TNBC animal model with limited responsiveness to chemotherapy, Telomir-1 demonstrated statistically significant activity ...

India’s pharmaceutical exports reached US$ 30.47 billion in FY 2024–25, and the sector remains optimistic about further growth, driven by strong global demand and resilient production capabilities.

Regeneron Pharmaceuticals (NASDAQ: REGN) underwent analysis by 21 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.

India, known for its generic drug industry, is rapidly transforming into a major hub for the global weight management ...